HR-3528-115
Placed on the Union Calendar, Calendar No. 582.
Sponsored by Katherine Clark (D-MA)
What it does
This bill would amend the Social Security Act to require that prescriptions for Schedule II–V controlled substances covered under Medicare Part D be transmitted electronically by the prescribing practitioner, effective January 1, 2021. The Secretary of Health and Human Services would be authorized to establish exceptions — including for economic hardship, technological limitations, hospice patients, nursing facility residents, research protocols, and emergencies — and to set penalties for non-compliance through rulemaking.
Who benefits
Medicare Part D enrollees who receive controlled substance prescriptions, who would gain a more secure and trackable prescription process. Pharmacists and pharmacy benefit managers who would receive standardized, legible electronic prescriptions. Law enforcement and public health agencies working to reduce prescription drug diversion and fraud. Health information technology vendors whose e-prescribing platforms would see increased adoption. Insurers and Medicare administrators who could more easily audit prescription patterns for fraud and abuse.
Who is hurt
Prescribers — particularly those in rural or underserved areas — who lack the technology infrastructure or financial resources to implement e-prescribing systems, even with the hardship waiver process. Small or solo medical practices that would face upfront costs to upgrade or adopt compliant electronic health record systems. Elderly or low-income Medicare patients in areas with limited pharmacy technology access. Practitioners who serve hospice or nursing facility populations and must navigate the waiver process. Practitioners who fail to comply could face financial penalties established by HHS rulemaking.
Supporters argue
Supporters argue that paper and fax prescriptions for controlled substances are a well-documented vector for fraud, forgery, and drug diversion, contributing to the opioid epidemic. They contend that e-prescribing creates an auditable electronic trail that makes it significantly harder to alter, forge, or duplicate prescriptions, and that New York State's 2016 e-prescribing mandate demonstrated measurable reductions in fraudulent prescriptions. They further argue that the bill's broad waiver provisions protect vulnerable practitioners and patients from undue hardship while still advancing a meaningful public health goal.
Opponents argue
Opponents argue that mandating e-prescribing as a condition of Medicare Part D coverage imposes a costly and burdensome technology requirement on small practices and rural providers who already face resource constraints, and that the waiver process — determined by HHS rulemaking — may prove difficult to navigate in practice. They contend that the bill delegates broad penalty authority to the Secretary without clear statutory guardrails, raising concerns about regulatory overreach, and that post-Loper Bright, courts will independently scrutinize whether HHS's implementing rules stay within the bill's statutory boundaries.
Constitutional context
Congress has broad authority to set conditions on Medicare Part D coverage under the Taxing and Spending Clause (Art. I, §8, cl. 1), and NFIB v. Sebelius (2012) affirmed that Congress may attach conditions to federal program participation. The bill's delegation of penalty-setting and waiver authority to HHS through rulemaking is subject to heightened judicial scrutiny following Loper Bright v. Raimondo (2024), under which courts will independently assess whether HHS's implementing rules fall within the statute's authorized scope rather than deferring to the agency's interpretation.
Checks and balances
Congress sets the e-prescribing mandate and its scope; HHS gains rulemaking authority to define exceptions and penalties; courts retain independent review of HHS rules under post-Loper Bright standards, and affected practitioners may challenge penalty regulations through administrative and judicial proceedings.
Historical precedent
New York State enacted a mandatory e-prescribing law for controlled substances in 2016, and the Medicare Improvements for Patients and Providers Act of 2008 previously established voluntary e-prescribing incentives under Part D.